Sharlene M Day

List of Publications by Year in Descending Order

68 papers	2,205 citations	24 h-index	46 g-index
84 ext. papers	3,081 ext. citations	10.1 avg, IF	4.75 L-index

#	Paper	IF	Citations
68	Translation of New and Emerging Therapies for Genetic Cardiomyopathies.. *JACC Basic To Translational Science*, **2022**, 7, 70-83	8.7	0
67	Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure.. *Journal of Clinical Investigation*, **2022**, 132,	15.9	3
66	Sex-Related Differences in Genetic Cardiomyopathies.. *Journal of the American Heart Association*, **2022**, e024947	6	1
65	Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy.. *Circulation: Heart Failure*, **2022**, CIRCHEARTFAILURE121009521	7.6	1
64	A Parallel Need for Cardiovascular Care for Female Carriers of Duchenne and Becker Muscular Dystrophy.. *Journal of Cardiac Failure*, **2022**,	3.3	1
63	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003062	5.2	10
62	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	5
61	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 1988-1996	9.5	20
60	Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2021**, 10, e019944	6	2
59	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. *Genetics in Medicine*, **2021**, 23, 1281-1287	8.1	3
58	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2021**, 17, 303-313	3.3	4
57	Response to Suay-Corredera et al. *Genetics in Medicine*, **2021**, 23, 2011-2012	8.1	
56	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. *Genetics in Medicine*, **2021**, 23, 69-79	8.1	4
55	Discordant clinical features of identical hypertrophic cardiomyopathy twins. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
54	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3932-3944	9.5	6
53	Women Representation Among Cardiology Journal Editorial Boards. *Circulation*, **2020**, 141, 603-605	16.7	16
52	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 141, 828-842	16.7	66

51	Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. *JCI Insight*, **2020**, 5,	9.9	20
50	Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology. *JCI Insight*, **2020**, 5,	9.9	5
49	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 83-91	16.2	23
48	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, **2020**, 142, e558-e631	16.7	77
47	Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. *Circulation Genomic and Precision Medicine*, **2020**, 13, e000067	5.2	59
46	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry. *Circulation: Heart Failure*, **2020**, 13, e007230	7.6	16
45	Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 396-405	5.2	19
44	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. *Circulation*, **2020**, 141, 1371-1383	16.7	43
43	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. *Genome Medicine*, **2019**, 11, 5	14.4	54
42	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". *Circulation*, **2019**, 139, 1559-1560	16.7	2
41	Nonobstructive Hypertrophic Cardiomyopathy-The High-Hanging Fruit. *JAMA Cardiology*, **2019**, 4, 235-236	16.2	3
40	17-β-estradiol ameliorates age-associated sarcopenia and improves late-life physical function in male mice but not in females or castrated males. *Aging Cell*, **2019**, 18, e12920	9.9	23
39	Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. *International Journal of Cardiology*, **2019**, 274, 226-231	3.2	4
38	MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2019**, 127, 165-173	5.8	24
37	Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. *Pflugers Archiv European Journal of Physiology*, **2019**, 471, 781-793	4.6	17
36	Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. *Circulation*, **2018**, 137, 419-421	16.7	20
35	Whole-Exome Sequencing Reveals and Mutations as a Potential Digenic Cause of Left Ventricular Noncompaction. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001966	5.2	4
34	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. *Heart Failure Clinics*, **2018**, 14, 119-128	3.3	22

33	Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup. *Genetics in Medicine*, **2018**, 20, 69-75	8.1	21
32	Response by Saberi and Day to Letter Regarding Article, "Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart". *Circulation*, **2018**, 138, 333-334	16.7	
31	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation*, **2018**, 138, 1387-1398	16.7	210
30	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2018**, 11, e005191	7.6	21
29	The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. *JAMA Cardiology*, **2017**, 2, 419-428	16.2	35
28	Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome. *JACC Basic To Translational Science*, **2017**, 2, 122-131	8.7	1
27	Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 317, 1349-1357	27.4	107
26	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. *Circulation: Cardiovascular Genetics*, **2017**, 10,		27
25	Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. *Journal of Cardiovascular Magnetic Resonance*, **2017**, 19, 107	6.9	22
24	Exercise for Patients With Hypertrophic Cardiomyopathy-Reply. *JAMA - Journal of the American Medical Association*, **2017**, 318, 481-482	27.4	1
23	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
22	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. *Open Heart*, **2017**, 4, e000615	3	15
21	Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. *Journal of Immunology*, **2016**, 197, 2353-61	5.3	35
20	Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection. *Virology*, **2016**, 498, 57-68	3.6	15
19	Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, **2016**, 99, 197-206	5.8	25
18	Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6701-6	11.5	68
17	Differential protein expression and basal lamina remodeling in human heart failure. *Proteomics - Clinical Applications*, **2016**, 10, 585-96	3.1	16
16	Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy. *Circulation*, **2016**, 134, 1738-1748	16.7	50

15	Exercise Prescription for the Athlete with Cardiomyopathy. *Cardiology Clinics*, **2016**, 34, 591-601	2.5	4
14	Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis. *Journal of Virology*, **2015**, 89, 468-79	6.6	28
13	Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy. *Clinics in Sports Medicine*, **2015**, 34, 489-505	2.6	14
12	Supercomputing for the parallelization of whole genome analysis. *Bioinformatics*, **2014**, 30, 1508-13	7.2	41
11	Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2014**, 7, 434-43		58
10	Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. *Circulation: Heart Failure*, **2013**, 6, 544-9	7.6	35
9	Cardiac risks associated with marathon running. *Sports Health*, **2010**, 2, 301-6	4.7	23
8	Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. *Circulation* , **2010**, 121, 997-1004	16.7	173
7	Exercise in hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2009**, 2, 407-14	3.3	12
6	Tuning cardiac performance in ischemic heart disease and failure by modulating myofilament function. *Journal of Molecular Medicine*, **2007**, 85, 911-21	5.5	31
5	Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. *Nature Medicine*, **2006**, 12, 181-9	50.5	94
4	Genetic engineering and therapy for inherited and acquired cardiomyopathies. *Annals of the New York Academy of Sciences*, **2006**, 1080, 437-50	6.5	4
3	Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. *Blood*, **2005**, 105, 192-8	2.2	244
2	Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. *Circulation*, **2003**, 107, 2601-6	16.7	137
1	Hypertrophic Cardiomopathy106-115		